価格
  1. 米国企業
  2. Aclarion, Inc.
  3. Raw

Aclarion, Inc.【ACON】

時価総額
$187.5万
PER
MRSを用いた椎間板性腰痛の非侵襲診断技術の新興企業。NOCISCANなどの定量的バイオマーカー解析を用いる診断プラットフォームを展開。2022年4月のIPOと2025年1月・3月の逆株式分割(1:335、1:27)実施、従業員6名体制。米国中心に展開、2025年Q1にPHILIPSとの初顧客連携開始。
株価業績
サマリーテーブルに戻る
2022年
12月31日		2023年
12月31日		2024年
12月31日
Net income (loss)-7,605,542-4,911,374-6,992,927
Depreciation and amortization--193,139
Share-based compensation1456,001287,455
Amortization of deferred issuance costs-497,656471,387
Changes in fair value of warrants and derivative--646,319-335,033
Non-cash interest related to bridge funding-98,68558,002
Gain (Loss) on exchange of debt--1
Loss on extinguishment of debt---111,928
Non-cash expenses related to equity line agreement--425,367
Accounts receivable12,2901,491-7,271
Prepaids and other current assets267,38338,539287,663
Accounts payable-603,102220,633-156,403
Accrued and other liabilities1448,459-127,449
Accrued interest on promissory and convertible notes200,712-6,190-
Net cash (used in) operations-5,314,171-3,646,947-5,271,609
Fixed assets--5,115
Intangible assets - Patents208,870119,522316,822
Net cash (used in) investing activities-207,870-119,522-321,937
Bridge funding cash issuance costs-323,301-
Equity line cash issuance costs--367,865
Preferred stock cash issuance costs--90,000
Common stock cash issuance costs--788,099
Proceeds from equity line-12
Proceeds from issuance of promissory notes-2-
Proceeds from sale of preferred stock-1,0001,000,000
Redemption of preferred stock-1,000-
Proceeds from sale of common stock and warrants, Reg A+--529,254
Proceeds from sale of common stock and warrants, ATM--288,294
Repayment of promissory notes2-300,973
Proceeds from sale of common stock and warrants related to public offering--3
Net cash provided by financing activities735
Net increase (decrease) in cash and cash equivalents1-451,737-567,408
Cash paid for interest--13,072
Issuance of warrants related to bridge funding-67,500-
Original issuance discount (15%) related to bridge funding-344,118-
Liability to issue common shares345,24333,297-
Issuance of commitment shares related to bridge funding-175,619-
Fair value of warrants and derivative related to first tranche bridge funding-742,988-
Fair value of warrants and derivative related to second tranche bridge funding-153,810-
Fair value of warrants and derivative related to third tranche bridge funding-160,012-
Dividends accrued on preferred shares415,523-59,675
Exchange of indebtedness for common shares--2
Exchange of indebtedness for preferred shares--930,052
Conversion of preferred stock to common stock26-129,999
Issuance of common shares related to restricted stock units--216,597
Issuance of commitment shares related to bridge funding--33,297